To ensure successful scale-up of continuous processing to large-scale production, it is
necessary to seamlessly incorporate viral testing and clearance/inactivation into …

Successful implementation of continuous processing requires an understanding of how to
incorporate viral testing and clearance/inactivation into the process via representative small …

The continuous processing session at the 2023 Viral Clearance Symposium (VCS) focused
on understanding how to effectively design viral clearance operations for use in continuous …

This article introduces the white paper from the 2017 Viral Clearance Symposium. The 5th
Viral Clearance Symposium in Penzberg, Germany, addressed regulatory perspectives …

This report provides a high-level summary of the key outcomes and gaps based on the
research presented at the 2019 Viral Clearance Symposium and identifies new areas for …

Virus removal by filtration has been an important improvement for the safety margins of
plasma-derived medicinal products and has become a standard manufacturing process step …

Viral clearance and inactivation are critical steps in ensuring the safety of biological products
derived from mammalian cell culture and are a component of an adventitious agent control …

There has been a recent drive in commercial large‐scale production of biotechnology
products to convert current batch mode processing to continuous processing manufacturing …

Viral clearance studies are mandated prior to entering clinical trials and for commercial
launch of biopharmaceuticals. These studies are a key component of risk mitigation to …

A continuous viral inactivation (CVI) tubular reactor was designed for low pH viral
inactivation within a continuous downstream system across multiple scales of operation. The …